⚡ Quick Start — If You Read Nothing Else

The most important things to know right now.

PKU is detected at birth through newborn screening. A blood spot test performed in the first 24–48 hours of life identifies elevated phenylalanine (Phe) levels. Universal newborn screening has been standard in the US since the 1960s, making PKU one of the earliest conditions screened for at birth.
Diet is the foundation of PKU management. A low-phenylalanine diet, started in the first days of life, prevents the intellectual disability that untreated PKU causes. This diet must be maintained for life — not just during childhood.
Medical formula is essential, not optional. Because the PKU diet severely limits natural protein intake, patients must consume a Phe-free amino acid medical formula to get adequate protein, vitamins, and minerals. Skipping formula leads to nutritional deficiencies.
Blood Phe targets matter throughout life. The ACMG recommends maintaining blood Phe between 120–360 μmol/L (2–6 mg/dL) at all ages. Elevated Phe in adults causes executive function problems, mood disturbances, and difficulty concentrating, even without overt intellectual disability.
About 25–50% of PKU patients respond to sapropterin (Kuvan). This oral medication is a synthetic form of BH4, the natural cofactor for the PAH enzyme. Responders can increase dietary Phe tolerance, sometimes substantially. A BH4 loading test determines who responds.
Pegvaliase (Palynziq) is a game-changer for adults with uncontrolled Phe. This injectable enzyme substitution therapy can reduce blood Phe to near-normal levels in adults who cannot achieve control with diet and sapropterin alone. It requires monitoring for anaphylaxis risk.
A newer pill, sepiapterin (Sephience), was FDA-approved in 2025. It is a next-generation BH4-pathway therapy (oral) approved for ages 1 month and older. In trials it helped some people who did not respond to the older drug sapropterin (Kuvan) and allowed more natural protein in the diet. A response test determines who benefits.
Gene therapy is in clinical trials. Multiple programs are investigating one-time gene therapy to restore PAH enzyme activity. While early results are promising, no gene therapy is yet FDA-approved for PKU.
Maternal PKU is a medical emergency for the fetus. Women with PKU who become pregnant with elevated Phe levels risk severe birth defects in their babies (who may not themselves have PKU). Phe levels must be at target before conception and maintained throughout pregnancy.

▼ Collapse

⏰ Your PKU Action Clock

PKU is a lifelong condition, and the calendar below turns that into concrete milestones. The one rule that never changes: the Phe-restricted diet and medical formula are for life. The questions in each phase are verbatim scripts you can read aloud to your metabolic team.

First 48 hours after a positive newborn screen.

A confirmatory blood test (plasma amino acids) and referral to a metabolic center should happen within the first 48 hours of a positive screen.
BH4 deficiency (a different condition that also raises Phe) is ruled out with urine pterins and a DHPR assay.

Within the first week.

The Phe-restricted diet and Phe-free medical formula are started — treatment should begin within 7–10 days of life. Every day of delay with high Phe matters for the developing brain.
A question to bring to that first appointment: Ask: “What exact blood Phe target range are we aiming for, and how often should we test at home?”

In the first month.

Regular (usually weekly) blood Phe monitoring is set up with home blood-spot cards, and a BH4 loading test checks whether sapropterin is likely to help.
A script for the responsiveness discussion: Ask: “Am I (or is my child) a candidate for a sapropterin or sepiapterin responsiveness trial, and what number counts as a real response?”

By month 3 — and every visit for life.

Phe tolerance, formula dose, and nutrition labs are reviewed at each visit. For adults whose Phe stays above target despite diet, pegvaliase candidacy is discussed.
A script for that conversation: Ask: “If diet and BH4 therapy are not enough for me, am I a candidate for pegvaliase (Palynziq), and how would the anaphylaxis boxed warning and the REMS observation period work in practice?”

Before any pregnancy — plan months ahead.

For anyone who could become pregnant: blood Phe must be in the 120–360 μmol/L range for at least 3 months before conception and throughout pregnancy, because uncontrolled maternal Phe is teratogenic — it can cause microcephaly, congenital heart defects, and intellectual disability in a baby who does not even have PKU.
A script to open that planning conversation: Ask: “I am thinking about pregnancy — what does my blood Phe need to be before I conceive, and what is our plan to get there and stay there safely?”

Understanding Phenylketonuria

Phenylketonuria (PKU) is an inherited metabolic disorder caused by mutations in the gene that produces phenylalanine hydroxylase (PAH), the enzyme responsible for converting the amino acid phenylalanine (Phe) into tyrosine. When PAH is absent or deficient, phenylalanine accumulates in the blood and brain to toxic levels, causing irreversible brain damage if left untreated.

PKU is an autosomal recessive condition — both parents must carry a PAH gene mutation for a child to be affected. Carriers (people with one mutation) are unaffected. Over 1,100 different PAH mutations have been identified, which is why PKU severity varies so widely among patients.

The good news: PKU was the first genetic disorder to be successfully treated through dietary modification, and the first condition to have universal newborn screening. Decades of experience show that early treatment prevents the most severe consequences. Today, the focus has shifted to optimizing lifelong outcomes, including cognitive function, mental health, and quality of life.

Approximately 1 in 10,000 to 1 in 15,000 births in the United States
Approximately 16,000 people currently living with PKU in the US
Higher prevalence in populations of Northern European and Irish descent (up to 1 in 4,500 in Ireland)
Lower prevalence in populations of African, Japanese, and Finnish descent
Universal newborn screening has been in place in all US states since the 1960s
Approximately 1 in 50 people in the US carries a single PAH mutation (carriers are unaffected)

Untreated PKU causes severe, irreversible consequences:

Intellectual disability: Severe (IQ typically below 50) and progressive if not treated early
Seizures: Common in untreated individuals
Behavioral problems: Hyperactivity, aggression, self-injurious behavior
Eczema-like skin rashes
Musty or mousy body odor (from phenylacetic acid, a Phe metabolite)
Lighter skin, hair, and eye color than family members (because Phe competes with tyrosine, the precursor for melanin)
Microcephaly: Smaller head circumference

These consequences are almost entirely preventable with early dietary treatment. This is why newborn screening is so critically important.

The most important concept in this guide: PKU management is lifelong. The old advice that patients could relax dietary restrictions after childhood was wrong and has been abandoned. Adults with elevated Phe experience measurable cognitive and psychological effects, including difficulty with executive function, processing speed, mood regulation, and quality of life. Diet and treatment are for life.

Key Breakthroughs in PKU

PKU management has evolved dramatically from diet-only treatment to a growing portfolio of pharmacological and genetic therapies:

FDA-APPROVED Sapropterin dihydrochloride (Kuvan) was the first FDA-approved pharmacological treatment for PKU. It is a synthetic form of tetrahydrobiopterin (BH4), the natural cofactor that PAH requires to function. In patients with residual PAH enzyme activity, sapropterin can enhance the enzyme’s function, lowering blood Phe and increasing dietary Phe tolerance. The PRISM trials demonstrated that approximately 25–50% of PKU patients are BH4-responsive, with the best responses seen in those with milder PAH mutations.

FDA-APPROVED Pegvaliase-pqpz (Palynziq) is a PEGylated recombinant phenylalanine ammonia lyase (PAL) enzyme. Unlike sapropterin, which enhances the body’s own PAH, pegvaliase provides a completely different enzyme that breaks down phenylalanine through a different metabolic pathway. It works regardless of PAH mutation type. The PRISM-301 and PRISM-302 trials showed that pegvaliase reduced blood Phe levels to below 360 μmol/L in a majority of patients, with many achieving near-normal levels (<120 μmol/L). However, it requires self-injection and carries risk of anaphylaxis, requiring a REMS program.

INVESTIGATIONAL Gene therapy for PKU aims to deliver a functional copy of the PAH gene, potentially providing a one-time treatment that restores normal Phe metabolism. Key programs include:

HMI-103 (Homology Medicines): An investigational, nuclease-free gene-editing therapy (pheEDIT trial, NCT05222178) — not FDA-approved
BMN 307 (BioMarin): An AAV5-based gene therapy program that was discontinued in 2023 after a clinical hold due to hepatocellular carcinoma findings in a long-term animal study; BioMarin is pursuing next-generation approaches
mRNA-based approaches: Early-stage programs exploring mRNA delivery of PAH enzyme as a potential repeat-dosing alternative to one-time gene therapy

Gene therapy for PKU is not yet available outside of clinical trials. Results from ongoing studies will determine whether these approaches can achieve durable, safe Phe reduction.

ADJUNCTIVE Large neutral amino acids (LNAAs) compete with phenylalanine for transport across the blood-brain barrier. Supplementation with LNAAs (tyrosine, tryptophan, branched-chain amino acids, and others) may reduce the amount of Phe entering the brain, even when blood Phe levels remain elevated. LNAA supplements are available as medical foods. Evidence for their efficacy is more limited than for sapropterin or pegvaliase, and they are generally considered an adjunctive strategy rather than a primary treatment.

Newborn Screening — How PKU Is Found

PKU is typically detected through newborn screening, a public health program that tests every baby born in the US within the first 24–48 hours of life.

A few drops of blood are taken from the baby’s heel and placed on a filter paper card (Guthrie card). The blood is analyzed using tandem mass spectrometry (MS/MS) to measure phenylalanine levels. If Phe is elevated above the state’s cutoff (typically >120–150 μmol/L or >2–2.5 mg/dL), a repeat test is ordered, and if confirmed, the baby is referred to a metabolic specialist.

Timeline: Results are typically available within 3–7 days. If positive, treatment should begin within the first 7–10 days of life. Earlier is better — every day of delay with high Phe levels matters for brain development.

After a positive newborn screen, confirmatory tests include:

Repeat plasma amino acid analysis: Quantitative measurement of blood Phe and Phe:Tyr (phenylalanine to tyrosine) ratio
Urine pterin analysis and DHPR assay: To rule out BH4 deficiency (a different condition that causes high Phe but requires different treatment)
PAH genotyping: Identifies the specific PAH mutations, which helps predict disease severity and BH4 responsiveness

What were my child’s specific phenylalanine levels on newborn screening?
Has BH4 deficiency been ruled out?
What PAH mutations does my child have, and what do they predict about severity?
Should a BH4 loading test be done to check for sapropterin responsiveness?
What blood Phe target should we be aiming for?
How often should blood Phe levels be checked?
When should we see a metabolic dietitian?
Is genetic counseling available for family planning?

PKU Classification

PKU is classified by severity based on blood phenylalanine levels before treatment. This classification helps predict dietary Phe tolerance and guide treatment decisions.

Classification	Untreated Blood Phe	Phe Tolerance	What This Means
Mild HPA	120–360 μmol/L (2–6 mg/dL)	Often unrestricted	Mild hyperphenylalaninemia. May not require dietary restriction. Monitoring recommended.
Mild PKU	360–600 μmol/L (6–10 mg/dL)	400–600 mg Phe/day	Requires dietary Phe restriction. Good BH4 response likelihood. More dietary flexibility than classic PKU.
Moderate PKU	600–1,200 μmol/L (10–20 mg/dL)	200–400 mg Phe/day	Requires strict dietary management. Some patients may respond partially to BH4.
Classic PKU	>1,200 μmol/L (>20 mg/dL)	200–250 mg Phe/day	Most severe form. Requires very strict dietary restriction. Least likely to respond to BH4. Most benefit from pegvaliase.

Important: Classification is a starting point, not a rigid category. Individual Phe tolerance varies based on specific PAH mutations, residual enzyme activity, growth rate, illness, and other factors. Two patients with the same classification can have different experiences. Work with your metabolic team to find your individual tolerance.

BH4 Responsiveness Testing

A BH4 loading test determines whether a patient’s PAH enzyme responds to tetrahydrobiopterin supplementation. This directly determines whether sapropterin (Kuvan) therapy will be effective.

A single dose of BH4 (typically 20 mg/kg) is given, and blood Phe is measured at baseline, 8 hours, and 24 hours. A reduction in Phe of 30% or more from baseline generally indicates BH4 responsiveness.

Who should be tested: The ACMG recommends that all newly diagnosed PKU patients undergo a BH4 loading test, regardless of initial severity classification. Some patients with classic PKU have mutations that partially respond to BH4.

Predictors of responsiveness: Patients with at least one mild PAH mutation have the highest likelihood of BH4 response. Genotype-phenotype databases can help predict responsiveness before testing.

What is my (or my child’s) PKU classification based on initial Phe levels?
What specific PAH mutations were found, and what do they predict about Phe tolerance?
Has a BH4 loading test been done? What were the results?
Am I a candidate for sapropterin (Kuvan)?
What is my daily phenylalanine tolerance?
How will we monitor for BH4 deficiency (a different condition)?

Dietary Management — The Foundation

Diet remains the cornerstone of PKU treatment. The goal is to limit phenylalanine intake to maintain blood Phe within the therapeutic range (120–360 μmol/L) while providing adequate nutrition for growth and health.

Phenylalanine is an essential amino acid found in virtually all protein-containing foods. Since the body cannot eliminate excess Phe, the diet must carefully control intake:

Eliminated or severely restricted: Meat, fish, poultry, eggs, dairy, nuts, beans, soy, regular bread, and most grains
Allowed in measured amounts: Some fruits, vegetables, and specially manufactured low-protein foods
Freely allowed: Pure fats (oils, butter), pure sugars, and most spices
Aspartame must be avoided: This artificial sweetener contains phenylalanine. Check all diet drinks, sugar-free gum, and medications

Typical daily Phe tolerance ranges from 200–600 mg/day depending on PKU severity, compared to approximately 2,000–4,000 mg/day in a typical unrestricted diet.

Specialty low-protein products help make the PKU diet more varied and sustainable:

Low-protein bread, pasta, rice, and baking mixes
Low-protein flour for home baking
Low-protein cheese and dairy substitutes
Specialty snacks and treats

Access and cost: These products are expensive ($5–15 per item) and often not covered by insurance in many US states. Some states have medical food legislation requiring coverage. Advocacy organizations can help navigate coverage.

Blood Phe monitoring is essential to ensure dietary management is working:

Infants (0–12 months): Weekly blood Phe monitoring
Children (1–12 years): Every 1–2 weeks
Adolescents (13–17): Monthly minimum; more often if levels are unstable
Adults (≥18): Monthly minimum per ACMG guidelines
Pregnancy: Twice weekly

Most monitoring is done via home blood spot cards (similar to newborn screening) mailed to the metabolic lab.

The hardest part about PKU: The diet is socially restrictive and requires constant vigilance. Every meal, every restaurant visit, every social gathering requires planning. This burden is real, and acknowledging it is important. But the consequences of abandoning diet — even in adulthood — are measurable cognitive and psychological harm. Support from metabolic dietitians, peer communities, and family is essential.

Medical Formula — Nutritional Lifeline

Because the PKU diet restricts most natural protein sources, patients must consume a phenylalanine-free amino acid medical formula to meet protein requirements. This is not optional — it is as medically necessary as insulin for type 1 diabetes.

Infant formulas: Phe-free versions of standard infant formula (e.g., Periflex, PKU Anamix, Phenex)
Pediatric and adult formulas: Available as powders, ready-to-drink liquids, and tablets/capsules
Glycomacropeptide (GMP)-based formulas: Made from a natural whey protein that is naturally low in Phe. Better taste than traditional amino acid formulas. Examples include Glytactin products
Low-volume concentrated formulas: For patients who struggle with the volume of standard formulas

Compliance challenge: Many patients, especially adolescents and adults, struggle with formula compliance due to taste, volume, and social stigma. Newer GMP-based and concentrated products improve palatability. Splitting formula intake across multiple doses throughout the day can help.

What is my recommended daily phenylalanine tolerance?
Which medical formula is best for me (amino acid vs. GMP-based)?
How much formula should I take each day, and how should I split doses?
Am I a candidate for sapropterin (Kuvan) or pegvaliase (Palynziq)?
What micronutrient supplements do I need beyond formula?
Does my insurance cover medical formula and low-protein foods?
How can I access a PKU-specialized metabolic dietitian?
Are there clinical trials I should know about?

Sapropterin (Kuvan) — BH4 Therapy

FDA-APPROVED 2007 Sapropterin dihydrochloride (Kuvan) is a synthetic form of BH4, the cofactor that the PAH enzyme requires to convert phenylalanine to tyrosine. In patients with residual PAH enzyme activity, sapropterin can boost enzyme function.

Many PAH mutations produce an enzyme that is misfolded but retains some catalytic activity. BH4 acts as a pharmacological chaperone, stabilizing the enzyme and enhancing its function. This allows the body to process more phenylalanine, resulting in:

Lower blood Phe levels on the same diet
Increased Phe tolerance: Patients can eat more natural protein, making the diet less restrictive
Better quality of life: More dietary freedom and social normalcy

Dosing: Standard dose is 5–20 mg/kg/day, taken once daily dissolved in water or apple juice, taken with food. Most patients start at 10 mg/kg/day. Response is evaluated over 1–4 weeks with blood Phe monitoring.

Approximately 25–50% of PKU patients show meaningful response to sapropterin, with response rates highest among those with mild to moderate PKU. Key findings from the sapropterin pivotal trials (the PKU-00x program — not to be confused with the pegvaliase PRISM trials):

PKU-003 (Levy 2007): Sapropterin reduced blood Phe significantly more than placebo in BH4-responsive patients
PKU-006 (withdrawal study): Discontinuing sapropterin caused blood Phe to rise, confirming the effect was real
Response is determined by PAH genotype. Common responsive mutations include p.R261Q, p.Y414C, p.A403V, and p.E390G
Some patients with classic PKU do respond — a BH4 loading test should be offered to all

Sapropterin does NOT replace diet. Even patients who respond to sapropterin still require some degree of dietary Phe restriction and continued medical formula intake. Sapropterin increases Phe tolerance but rarely eliminates the need for dietary management entirely.

Sephience (sepiapterin) — Next-Generation BH4 Therapy

FDA-APPROVED 2025 Sepiapterin (Sephience, PTC Therapeutics) is an oral precursor of tetrahydrobiopterin (BH4) — the same cofactor that sapropterin supplies, but delivered one step earlier in the synthesis pathway. Because cells convert sepiapterin to BH4 internally, it can raise BH4 levels and stabilize the PAH enzyme even in some patients who did not respond to sapropterin. The FDA approved it on 28 July 2025 for hyperphenylalaninemia in adults and children aged 1 month and older with sepiapterin-responsive PKU, across all disease severities. It is the third FDA-approved Phe-lowering medication.

What the APHENITY trial showed. In the phase 3 APHENITY study (NCT05099640), sepiapterin lowered blood phenylalanine by about 63% on average, and 97% of responders were able to safely increase their natural protein intake. A meaningful share of patients who had not responded to sapropterin did respond to sepiapterin. Like other BH4-pathway therapies, sepiapterin is used alongside — not instead of — dietary management, and a response test determines who benefits.

Sepiapterin comes as an oral powder (250 mg or 1000 mg sachets) that is mixed into water, apple juice, or soft food and taken once daily with a meal. The dose is based on age and body weight:

0 to under 6 months: 7.5 mg/kg once daily
6 to under 12 months: 15 mg/kg once daily
12 months to under 2 years: 30 mg/kg once daily
2 years and older (children and adults): 60 mg/kg once daily

The response test. In the trial, a two-week (14-day) trial was used to see who responds — a drop in blood Phe of at least 15% counted as a response. If your Phe does not fall meaningfully after an adequate trial, the medication is stopped rather than continued.

A script for that conversation: Ask: "Can we do a two-week sepiapterin trial with my blood Phe checked before and after, and agree in advance that we stop it if my Phe does not drop by at least 15%?"

In the APHENITY trial (222 people in the combined safety group), the most common side effects were generally mild:

Upper respiratory (cold-like) infections — about 20%
Headache — about 15%
Diarrhea — about 15%
Stomach (abdominal) pain — about 12%
Discolored stool — about 5%
Blood Phe dropping too low (hypophenylalaninemia) — about 3%; your team may add natural protein back if this happens

Long-term use is being followed in the APHENITY Extension study (NCT05166161), and a study of thinking and learning outcomes in children on sepiapterin (EPIPHENY, NCT06302348) is enrolling as of 2026.

International status: Also approved by the European Commission (19 June 2025), Health Canada (December 2025), and in Japan, Australia, and Switzerland (2025) — in each case with broad labeling across ages and PKU severities.

Pegvaliase (Palynziq) — Enzyme Substitution

FDA-APPROVED 2018 Pegvaliase-pqpz (Palynziq) is a PEGylated recombinant phenylalanine ammonia lyase (PAL) enzyme that converts phenylalanine to trans-cinnamic acid and ammonia via a pathway independent of PAH. It works regardless of PAH mutation type, making it effective even in classic PKU patients who do not respond to BH4.

The PRISM-1 (NCT01819727) and PRISM-2 (NCT01889862) pegvaliase Phase 3 trials demonstrated:

Mean blood Phe reduction of approximately 51–70% from baseline
A majority of patients achieved blood Phe <360 μmol/L (the ACMG upper target)
Many patients achieved blood Phe <120 μmol/L (near-normal levels)
Patients could significantly liberalize their diets while maintaining low Phe
Improvements in ADHD-like symptoms, mood, and attention reported

Anaphylaxis risk: Pegvaliase carries an FDA boxed warning for anaphylaxis. Approximately 9% of patients in clinical trials experienced anaphylaxis. It is available only through a REMS (Risk Evaluation and Mitigation Strategy) program. All patients must:

Carry an epinephrine auto-injector at all times
Be observed for at least 60 minutes after the first dose and at least 20 minutes for subsequent doses
Be trained to recognize and self-treat anaphylaxis
Have a caregiver trained in epinephrine administration

Other common side effects:

Injection site reactions (most common): redness, swelling, pain — occur in approximately 60% of patients, typically mild to moderate and decreasing over time
Joint pain (arthralgia)
Immune-mediated reactions including serum sickness-like reactions
Hypophenylalaninemia (Phe levels too low): Monitor and supplement Phe if needed

Age: Approved for adults (18+) with uncontrolled blood Phe levels (>600 μmol/L) on existing management
All PAH genotypes: Works regardless of specific mutations (unlike sapropterin)
Dosing: Self-administered subcutaneous injection. Starts at 2.5 mg weekly with gradual titration over months to a target dose of 20–40 mg daily
Not for: Pediatric patients (trials ongoing), pregnant women, patients unwilling to carry epinephrine

LNAA Supplementation

ADJUNCTIVE Large neutral amino acids (LNAAs) are amino acids that share the same transport system with phenylalanine to cross the blood-brain barrier. By supplementing with LNAAs, you can competitively reduce the amount of Phe entering the brain.

LNAA supplementation may reduce brain Phe concentration by 20–30%, based on limited studies
Evidence is primarily from small, short-term studies — no large randomized trials have been completed
LNAAs do NOT reliably lower blood Phe — they may reduce brain exposure even with elevated blood levels
Best considered as an adjunct for patients who cannot maintain adequate dietary control, not as a replacement for diet
Products include PreKUnil, PheBLOC, and some LNAA-enhanced amino acid formulas

Am I a candidate for pegvaliase (Palynziq)?
What is the process for starting pegvaliase, and how will anaphylaxis risk be managed?
How long does pegvaliase titration take before I see results?
Would LNAA supplementation benefit me in addition to my current treatment?
Are there gene therapy trials I might be eligible for?
If my Phe gets too low on pegvaliase, how do we manage that?

How Your PKU Therapies Work Together

PKU treatment is rarely an either/or choice between "diet" and "medication." The pieces are designed to combine, and understanding how they stack helps you have a better conversation with your team.

The low-Phe diet and the Phe-free medical formula are the foundation for every person with PKU, at every age. Medications are added on top of this backbone — not as replacements for it. Even a strong drug response does not remove the need for some dietary care and continued formula.

For people who respond to sapropterin (Kuvan) or sepiapterin (Sephience), the drug and the diet work in synergy: the medicine raises how much natural protein your body can safely handle, and the combined benefit lets many responders eat more normally while keeping blood Phe in the 120–360 μmol/L range. The diet is relaxed under monitoring, not abandoned.

A script to explore this: Ask: "If I respond to a BH4 medicine, how much more natural protein could I safely add, and how will we track that my Phe stays in range?"

Pegvaliase (Palynziq) is unusual: as it lowers blood Phe toward normal, many adults can replace much of their medical formula with ordinary food. Here the medication reduces formula dependence rather than stacking on top of it. The trade-off is the injection routine, the anaphylaxis precautions, and watching that Phe does not drop too low.

Large neutral amino acids (LNAAs) are an adjunct that stacks with diet — they may reduce how much Phe reaches the brain even when blood Phe is elevated. They do not replace dietary control or formula, and the evidence is more limited than for the approved drugs.

The synergy that matters most is adherence. Any therapy that improves your quality of life — more dietary freedom, fewer formula servings — tends to improve how consistently you stick with the whole plan, which amplifies your metabolic control beyond the drug's direct effect. The reverse is also true: adding a medication on top of an abandoned formula rarely rescues control. If things are slipping, reconnect with your dietitian first.

What PKU Treatment Costs — and How Coverage Works

PKU care is expensive, and what you actually pay depends heavily on insurance and which US state you live in. The prices below are list (wholesale) or cash prices as of July 2026 — your out-of-pocket cost is usually far lower once insurance and manufacturer copay support are applied. They are shown so you can ask informed questions, not so you can shop.

Sapropterin (generic for Kuvan): a 30-packet carton of 500 mg runs about $2,958 cash, or roughly $1,634 with a free GoodRx coupon (GoodRx, accessed July 2026). For comparison, the brand Kuvan 500 mg 30-packet carton lists at $6,300 and the 120-count of 100 mg tablets at $5,040 (BioMarin U.S. Product Price Reference, effective January 2021), so the generic is roughly half the brand price.
Pegvaliase (Palynziq): the manufacturer wholesale price (WAC) is $561 per single-dose prefilled syringe and $5,610 for a 10-syringe carton (BioMarin U.S. Product Price Reference, effective January 2022). At the common 20 mg once-daily maintenance dose that works out to roughly $200,000 a year at list price, which is why insurance approval and copay assistance are central to access.
Sepiapterin (Sephience): the newest pill. Cash price is about $3,824 for 30 sachets of 250 mg (Drugs.com, 2026). Analysts estimated a launch price near $40,000 a month (roughly $480,000–$492,000 a year, depending on weight); the official US list price was not published at launch, so confirm the real cost through your pharmacy and PTC's patient-support program.
Low-protein specialty foods: roughly $5–15 per item, and frequently not fully covered by insurance.

Item	US price (list/cash)	Source (dated)
Kuvan (brand) 500 mg, 30-packet carton	$6,300	BioMarin price reference, Jan 2021
Kuvan (brand) 100 mg, 120 tablets	$5,040	BioMarin price reference, Jan 2021
Kuvan (brand) 100 mg, 30-packet carton	$1,260	BioMarin price reference, Jan 2021
Sapropterin (generic) 500 mg, 30-packet carton	~$2,958 cash (~$1,634 with coupon)	GoodRx, 2026
Palynziq, single-dose syringe	$561 (~$5,610 per 10-syringe carton; ~$200,000/yr at 20 mg/day)	BioMarin price reference, Jan 2022
Sephience 250 mg, 30 sachets	~$3,824 cash	Drugs.com, 2026
Copay-program cost for many insured patients	as low as $0	Manufacturer patient-support programs

Medical formula and low-protein foods: more than 30 US states have medical-foods laws that require some insurance coverage, but coverage for adults varies widely from state to state. A metabolic clinic’s social worker or dietitian can tell you which state mandate applies to you.
Manufacturer assistance: BioMarin’s patient-support program offers copay assistance for eligible commercially insured patients; per BioMarin’s own price reference, many participating patients paid $0 out of pocket.
A script for the money conversation: Ask: “Before we start this medication, can your team help me confirm insurance coverage and enroll me in any copay or patient-assistance program?”

Clinical Trials — What Is Being Studied

PKU research is advancing rapidly. Several novel approaches are in clinical trials that could transform PKU management.

Program	Approach	Status	Note
Repinatrabit (JNT-517)	Oral pill that increases Phe loss in the urine (blocks the SLC6A19 amino-acid transporter); works regardless of genotype, no injection	Phase 3 (recruiting, 2026)	A new oral mechanism from Otsuka/Jnana. Long-term study NCT06628128 and efficacy study NCT06971731
Pegvaliase (pediatric, PEGASUS)	Enzyme substitution in ages 12–17	Phase 3	Expanding pegvaliase to adolescents — PEGASUS, NCT05270837 (~50% Phe reduction vs diet alone)
HMI-103 (Homology Medicines)	Gene-editing therapy (pheEDIT)	Phase 1 — terminated	pheEDIT (NCT05222178) is now listed as terminated; earlier HMI-102 (pheNIX, NCT03952156) also terminated
mRNA therapies	mRNA-encoded PAH enzyme delivery	Preclinical/early Phase 1	Multiple companies exploring; preclinical to Phase 1 stage — search ClinicalTrials.gov by drug name

Note: Trial status and availability change rapidly. Always verify current enrollment status at ClinicalTrials.gov by searching for “phenylketonuria” and filtering by status (recruiting) and location.

ClinicalTrials.gov (clinicaltrials.gov): Search “phenylketonuria” and filter by recruiting status and location
National PKU Alliance (NPKUA): Maintains a registry and advocates for trial access. npkua.org
Your metabolic center: Many centers participate in PKU trials. Ask your metabolic physician what is available
PKU clinical trial networks: Multi-site studies often recruit through specialized metabolic disease networks

Maternal PKU — Protecting the Baby

Maternal PKU syndrome is preventable but devastating if ignored. Women with PKU who have elevated blood Phe during pregnancy expose their developing baby to high phenylalanine levels, causing severe birth defects including intellectual disability, microcephaly, congenital heart defects, and intrauterine growth restriction — even if the baby does not have PKU.

Plan before pregnancy: Blood Phe must be at target (120–360 μmol/L) BEFORE conception. Ideally, Phe should be in range for at least 3 months before becoming pregnant
During pregnancy: Blood Phe should be monitored at least twice weekly and maintained at 120–360 μmol/L throughout all three trimesters
Strict dietary adherence is essential. Most women need to significantly restrict Phe intake and increase medical formula consumption during pregnancy
Sapropterin may be continued during pregnancy if the patient is an established responder. Discuss with your metabolic team and obstetrician
Pegvaliase is NOT approved for use during pregnancy. Women on pegvaliase who wish to become pregnant should discuss transition to dietary management well before conception
Folic acid supplementation (at least 400 μg/day, often higher) is recommended before and during pregnancy

When should I start planning for pregnancy?
Is my current Phe level safe for conception?
How often should I monitor blood Phe during pregnancy?
Should I continue or stop sapropterin during pregnancy?
If I am on pegvaliase, when should I stop before trying to conceive?
What additional nutritional support do I need during pregnancy?
Should my partner be tested for PAH carrier status?
What is the risk of my child having PKU?

Neuropsychological Impact of PKU

Even with early treatment, individuals with PKU may experience subtle but measurable neuropsychological effects, particularly when blood Phe levels are above the therapeutic range.

Executive function deficits: Difficulty with planning, organization, working memory, and mental flexibility. These are the most consistently documented effects in treated PKU
Processing speed: Slower reaction times and information processing compared to non-PKU peers
Attention difficulties: Higher rates of inattention (though not necessarily ADHD) have been reported
Mood disturbances: Higher rates of anxiety and depression, especially in adults with elevated Phe
White matter changes: Brain MRI may show white matter abnormalities, particularly in individuals with chronically elevated Phe. These changes may be partially reversible with improved Phe control

These effects are dose-dependent: higher and more variable Phe levels correlate with greater neuropsychological impact. Maintaining stable, in-range Phe levels minimizes these effects.

Should I (or my child) have neuropsychological testing?
Are my cognitive or mood symptoms related to PKU or Phe levels?
Is brain MRI indicated to check for white matter changes?
Would better Phe control improve my cognitive symptoms?
Are there educational accommodations available (for children in school)?
Should I see a neuropsychologist or psychiatrist with PKU experience?

International Access & Regulatory Landscape

PKU management options vary by country. Some therapies available in the US may not be accessible elsewhere, and vice versa.

Therapy	US FDA	EMA (Europe)	Health Canada	Notes
Sapropterin (Kuvan)	Approved 2007	Approved 2008	Approved 2009	Broadly available in developed countries
Sepiapterin (Sephience)	Approved Jul 2025	Approved Jun 2025	Approved Dec 2025	Next-gen BH4 precursor; ages 1 month+; also approved in Japan
Pegvaliase (Palynziq)	Approved 2018	Approved 2019	Approved Mar 2022 (≥16 y)	REMS program in US; requires trained prescribers
Medical formula	Available (coverage varies by state)	Covered in most EU countries	Covered in most provinces	Coverage for adults varies widely. Advocacy needed
Low-protein specialty foods	Coverage varies by state	Prescription coverage in most EU	Varies by province	30+ US states have medical foods laws

ACMG (US): 2014 PKU guidelines — comprehensive recommendations for diagnosis, treatment targets, and monitoring
European PKU Guidelines (2017): Evidence-based consensus for diagnosis and management across the lifespan
AHRQ (US): Systematic evidence review of PKU adjuvant therapies
NICE (UK): Technology appraisals for sapropterin and pegvaliase
JSIEM (Japan): Japanese guidelines for PKU management with emphasis on newborn screening integration

Failed & De-Adopted Therapies

Understanding what has been tried and did not work helps patients and families evaluate new options and avoid false hope from outdated approaches.

ABANDONED For decades, many clinicians advised that children with PKU could discontinue dietary restriction around age 6, after the most critical period of brain development. This was incorrect. Studies from the 1980s–2000s demonstrated that adults who relaxed diet experienced measurable declines in executive function, processing speed, and quality of life, and higher rates of anxiety and depression. All major guidelines now recommend lifelong dietary management.

DISCONTINUED BMN 307 was an AAV5-based liver-directed gene therapy developed by BioMarin for PKU. The program was placed on clinical hold by the FDA in 2021 after long-term animal toxicology studies showed hepatocellular carcinoma in mice. Although no tumors were observed in human participants, BioMarin ultimately discontinued the program in 2023 due to the safety signal and regulatory uncertainty. The company has indicated interest in pursuing next-generation gene therapy approaches with improved safety profiles.

SUPERSEDED Early attempts at enzyme replacement using unmodified phenylalanine ammonia lyase (PAL) enzyme were limited by rapid immune clearance and short half-life. The protein was quickly neutralized by the immune system after injection. PEGylation (coating with polyethylene glycol) solved this problem, leading to the development of pegvaliase (Palynziq), which has a longer half-life and sustained efficacy, though immune-related adverse events remain a challenge.

Why this matters: If someone suggests a therapy for PKU, ask: “Has this been tested in clinical trials for PKU, and what were the results?” The PKU field has a long history of well-intentioned approaches that did not pan out, and it is important to distinguish between evidence-based therapies and unproven claims.

Specialty Centers

PKU management is best delivered at centers with dedicated metabolic genetics programs, experienced metabolic dietitians, and access to the full range of therapies including sapropterin, pegvaliase, and clinical trials.

No endorsement. Listing a center here does not constitute an endorsement or recommendation. Trouvera has no financial relationship with any medical center listed unless explicitly disclosed. Patients should evaluate centers based on their own needs and in consultation with their medical team.

University of Utah Metabolic Clinic

Comprehensive inherited metabolic disease program within the Division of Medical Genetics

Location: University of Utah Health, Salt Lake City, UT
Phone: 801-581-2121
Programs: Lifelong PKU management, BH4 responsiveness testing, sapropterin and pegvaliase prescribing, metabolic dietitian services, genetic counseling, transition programs for adolescents, maternal PKU management.

Why it matters. The University of Utah has one of the longest-standing metabolic genetics programs in the western US, with decades of experience managing PKU across the lifespan. ARUP Laboratories (affiliated) provides newborn screening and amino acid analysis.

Primary Children’s Hospital PKU Program

Pediatric metabolic disease program within Intermountain Health

Location: 100 N Mario Capecchi Dr, Salt Lake City, UT 84113
Phone: 801-662-1000
Programs: Pediatric PKU management, newborn screening follow-up, metabolic dietitian services, family support and education.

Huntsman Cancer Institute — Genetics

Location: 2000 Circle of Hope Dr, Salt Lake City, UT 84112
Phone: 801-585-0303
Programs: Genetic counseling services; ARUP Laboratories for metabolic testing and amino acid analysis.

Intermountain Health

Phone: 801-442-2000
Programs: Integrated health system with metabolic disease support across Utah and the Intermountain West. Primary Children’s Hospital is the pediatric center of excellence within the system.

How to choose. University of Utah Metabolic Clinic = Academic center with full-spectrum lifelong PKU management, clinical trial access, ARUP diagnostics. Primary Children’s Hospital = Pediatric-focused within Intermountain Health, strong for newborn through adolescent care. Both collaborate closely.

Information verified May 2026. Availability changes — confirm with each institution directly.

Boston Children’s Hospital — Metabolism Program

Location: Boston, MA · Phone: 617-355-6000
One of the largest and most experienced PKU centers in the US. Full range of dietary and pharmacological management. Active clinical trial portfolio. Pioneers in PKU research.

Children’s Hospital of Philadelphia (CHOP) — Metabolism

Location: Philadelphia, PA · Phone: 215-590-1000
Comprehensive metabolic disease program. PKU management across lifespan. Research center for PKU therapies.

Mount Sinai — Metabolism Program

Location: New York, NY · Phone: 212-241-6947
Large metabolic disease center with dedicated PKU clinic. Pegvaliase and gene therapy trial experience.

Oregon Health & Science University (OHSU) — Metabolic Clinic

Location: Portland, OR · Phone: 503-494-8311
Regional referral center for metabolic diseases in the Pacific Northwest. PKU lifespan management.

University of Washington — Biochemical Genetics

Location: Seattle, WA · Phone: 206-598-3022
Academic center with strong metabolic genetics program and PKU clinical trial participation.

National Human Genome Research Institute (NHGRI/NIH)

Location: Bethesda, MD · Phone: 301-594-7487
NIH intramural program studying PKU genetics and treatment. Ongoing natural history studies.

Emory University — Genetics & Metabolism

Location: Atlanta, GA · Phone: 404-778-8500
Large inherited metabolic disease program. PKU across the lifespan. Southeast regional referral center.

VA Metabolic Disease Care

PKU in adults is managed through VA hematology, endocrinology, or internal medicine services, often with referral to affiliated academic metabolic centers. Veterans with PKU should ask about:

Referral to a metabolic genetics specialist through community care
Coverage for medical formula and low-protein specialty foods through the VA pharmacy benefit
Access to pegvaliase through the REMS program via VA specialty pharmacy

George E. Wahlen VA Medical Center: 801-582-1565 (Salt Lake City, UT) — academic partnership with University of Utah for metabolic care

Hospital for Sick Children (SickKids), Toronto

Location: 555 University Avenue, Toronto, ON M5G 1X8
Phone: 416-813-1500
Programs: One of North America’s largest pediatric metabolic programs. PKU lifespan clinic. Active in PKU clinical trials.

BC Children’s Hospital — Biochemical Diseases

Location: Vancouver, BC
Phone: 604-875-2345
Programs: Provincial referral center for inherited metabolic diseases including PKU.

Alberta Children’s Hospital, Calgary

Location: Calgary, AB
Phone: 403-955-7211
Programs: Metabolic disease program serving Alberta. PKU management and dietitian services.

Canadian PKU & Allied Disorders (CanPKU): canpku.org
Newborn Screening Ontario: Provincial screening programs across Canada include PKU

International Centers of Excellence for PKU

Great Ormond Street Hospital, London, UK: Major European metabolic diseases center. Active in PKU research and clinical trials
University Medical Center Hamburg-Eppendorf, Germany: Leading European center for amino acid disorders. PKU guideline development
Bambino Gesù Children’s Hospital, Rome, Italy: Italian reference center for PKU
National Center for Child Health and Development, Tokyo, Japan: Japanese reference center for PKU and newborn screening
Royal Melbourne Hospital, Australia: Australian metabolic disease referral center

Caregiver Guidance

Caring for a child or supporting an adult with PKU requires daily commitment to dietary management, medical formula, monitoring, and emotional support. The chronic nature of PKU creates unique challenges at every life stage.

Start treatment immediately. Begin the Phe-restricted formula within the first 7–10 days of life. Breastfeeding can often continue in measured amounts alongside PKU formula, guided by the metabolic dietitian.
Learn to count Phe. Every food must be measured and tracked. Apps and databases (e.g., PKU apps, USDA database) can help. Your metabolic dietitian will teach you.
Frequent blood tests. Infants need weekly blood Phe monitoring. Home blood spot cards reduce the burden of clinic visits.
Educate daycare and family. Anyone feeding the child must understand what the child can and cannot eat. A simple one-page guide can be lifesaving in preventing errors.

Teach self-management gradually. Children should learn to make their own food choices, count Phe, and prepare formula as they get older. Independence is the goal.
Social challenges are real. Birthday parties, school lunches, sleepovers, and eating out all require planning. Pack alternatives. Teach the child to explain their diet confidently.
Adolescence is the highest-risk period. Dietary adherence drops significantly in the teenage years due to desire for social normalcy, rebellion, and formula fatigue. Support, not punishment, is the effective response. Consider pharmacological therapies (sapropterin, pegvaliase) if diet alone is failing.
Neuropsychological monitoring. If academic performance or behavior changes, consider neuropsychological testing and blood Phe correlation.

Connect with the PKU community. The National PKU Alliance (npkua.org) offers family support, conferences, and peer connections. PKU camps (e.g., Camp PKU) provide age-appropriate social experiences with peers who understand the diet.
Mental health matters. Both patients and caregivers experience increased rates of anxiety. Acknowledge this and seek help when needed.
Caregiver burnout is real. The constant dietary vigilance is exhausting. Share the load with partners, family, and PKU-knowledgeable babysitters.

Medication Dosing at a Glance

These are the standard doses from the FDA prescribing information for each approved PKU medicine, as of 2026. Your own dose is set by your metabolic team based on your weight, age, and blood Phe response — use this only to ask informed questions.

Where these numbers come from: Kuvan (sapropterin) FDA label, 2007; Palynziq (pegvaliase) FDA label, 2018; Sephience (sepiapterin) FDA label, 2025; folic-acid guidance per the ACMG 2014 PKU guideline and the European PKU guideline, 2017. Trial evidence: the sapropterin PKU-003 trial (Levy et al., Lancet, 2007), the pegvaliase PRISM trial program (Thomas et al., 2018), and the sepiapterin APHENITY trial (2025).

Medicine	Typical dose (per FDA label)	How it is taken
Sapropterin (Kuvan)	Usually start around 10 mg/kg/day; range 5 to 20 mg/kg/day, once daily	Tablet or powder dissolved in water or apple juice, with food
Sepiapterin (Sephience)	By age: 7.5 mg/kg (under 6 mo), 15 mg/kg (6–12 mo), 30 mg/kg (1–2 yr), 60 mg/kg (2 yr and older), once daily. Sachets of 250 mg or 1000 mg	Oral powder mixed in water, apple juice, or soft food, with a meal
Pegvaliase (Palynziq)	Start 2.5 mg once weekly, then slowly titrate over 9+ months to 20 mg or 40 mg daily (max 60 mg daily)	Self-injected under the skin; epinephrine auto-injector carried at all times (REMS)
BH4 loading test	Single 20 mg/kg dose, with blood Phe checked at 0, 8, and 24 hours	One-time test to see if a BH4 medicine is likely to help
Folic acid (in pregnancy)	At least 400 mcg/day; many clinicians use 4 mg/day before and during pregnancy	Daily oral supplement

Verbatim Questions to Bring to Your Appointments

These are ready-to-read scripts. Copy the ones that fit your situation into your phone or a notebook and read them aloud at your next visit.

At and after diagnosis

Ask: "What were the exact phenylalanine numbers on the newborn screen, and has BH4 deficiency been ruled out?"
Ask: "What blood Phe target range are we aiming for, and how often should we test at home?"
Ask: "What PAH mutations do I have, and what do they predict about my Phe tolerance and drug response?"

Diet and medical formula

Ask: "What is my daily phenylalanine tolerance in milligrams, and how did you arrive at that number?"
Ask: "Which medical formula do you recommend for me, and how should I split the doses across the day?"
Ask: "Does my insurance cover medical formula and low-protein foods in my state, and can a social worker help?"

BH4 medicines (Kuvan and Sephience)

Ask: "Am I a candidate for a sapropterin or sepiapterin responsiveness trial, and what number counts as a real response?"
Ask: "If I did not respond to Kuvan, is it still worth trying Sephience, since they deliver BH4 differently?"

Pegvaliase (Palynziq)

Ask: "If diet and BH4 therapy are not enough, am I a candidate for pegvaliase, and how would the anaphylaxis precautions and REMS observation work day to day?"
Ask: "How long is the titration before we know if pegvaliase is working, and at what point would we stop it?"
Ask: "If my Phe drops too low on pegvaliase, how will we add protein back safely?"

Pregnancy and family planning

Ask: "I am thinking about pregnancy — what does my blood Phe need to be before I conceive, and what is our plan to get there and stay there?"
Ask: "Should I continue or stop each of my PKU medicines before trying to conceive?"

Living well with PKU

Ask: "Could my trouble with focus or mood be related to my Phe levels, and would tighter control help?"
Ask: "Should I have neuropsychological testing, and is there someone with PKU experience I can see?"

Costs, access, and trials

Ask: "Before we start this medicine, can your team confirm coverage and enroll me in any copay or patient-assistance program?"
Ask: "Is there a generic option that would lower my cost?"
Ask: "Are there PKU clinical trials I might qualify for, including the newer oral-pill trials, and would joining interrupt my current treatment?"

Glossary

Amino acid: Building blocks of protein. Phenylalanine is one of 20 standard amino acids.
Aspartame: An artificial sweetener that contains phenylalanine. Must be avoided by people with PKU.
Autosomal recessive: A pattern of inheritance where both copies of a gene must be mutated to cause disease. Both parents must be carriers.
BH4 (tetrahydrobiopterin): The natural cofactor required by the PAH enzyme. Deficiency of BH4 can also cause elevated Phe and must be ruled out.
BH4 loading test: A test where BH4 is given and blood Phe is monitored to determine if the patient responds to sapropterin therapy.
Blood Phe: The concentration of phenylalanine in the blood, usually measured in μmol/L or mg/dL. Target range: 120–360 μmol/L (2–6 mg/dL).
Carrier: A person with one normal and one mutated PAH gene. Carriers are unaffected but can pass the mutation to children.
Classic PKU: The most severe form with untreated Phe >1,200 μmol/L. Requires the most restrictive diet.
GMP (glycomacropeptide): A natural whey protein very low in phenylalanine, used to make palatable PKU medical formulas.
Guthrie card: The filter paper card used for newborn screening blood spot collection.
HPA (hyperphenylalaninemia): Elevated blood phenylalanine. Includes all forms from mild HPA to classic PKU.
LNAA: Large neutral amino acids. Compete with Phe for brain entry. Used as adjunctive therapy.
Maternal PKU syndrome: Birth defects caused by high maternal Phe levels during pregnancy, affecting the baby even if the baby does not have PKU.
Medical formula: Phenylalanine-free amino acid mixture providing protein, vitamins, and minerals essential for PKU patients.
PAH (phenylalanine hydroxylase): The liver enzyme that converts phenylalanine to tyrosine. Deficient or absent in PKU.
PAL (phenylalanine ammonia lyase): An enzyme (not naturally found in humans) that breaks down Phe via a different pathway. The basis of pegvaliase therapy.
Pegvaliase (Palynziq): FDA-approved enzyme substitution therapy for adults with PKU. Self-injected. Works regardless of PAH mutation type.
Phe tolerance: The amount of dietary phenylalanine (in mg/day) a person can consume while maintaining blood Phe in the therapeutic range.
Phe:Tyr ratio: Ratio of phenylalanine to tyrosine in the blood. Used to assess metabolic control. Elevated ratio indicates poor control.
PKU: Phenylketonuria. An inherited metabolic disorder caused by PAH deficiency, leading to toxic accumulation of phenylalanine.
REMS: Risk Evaluation and Mitigation Strategy. An FDA safety program required for pegvaliase due to anaphylaxis risk.
Sapropterin (Kuvan): FDA-approved synthetic BH4 cofactor. Enhances residual PAH enzyme activity in responsive patients.
Tandem mass spectrometry (MS/MS): The laboratory method used for newborn screening to detect elevated phenylalanine.
Tyrosine: An amino acid produced from phenylalanine by PAH. Deficient in PKU, requiring supplementation.

Sources and Further Reading

This guide draws on published medical literature, clinical trial records, and the work of physicians and researchers specializing in inborn errors of metabolism. Key sources are listed below.

Primary Resources

PubMed (pubmed.ncbi.nlm.nih.gov) — Free public database of medical research
ClinicalTrials.gov (clinicaltrials.gov) — Authoritative registry of clinical trials
National PKU Alliance (NPKUA) (npkua.org) — Patient advocacy, research registry, education
National Organization for Rare Disorders (NORD) (rarediseases.org) — PKU overview and resources
Genetics Home Reference (MedlinePlus) (medlineplus.gov) — Patient-friendly PKU information from the NIH

Key Guideline and Trial References

ACMG PKU Guidelines 2014: Vockley J, Andersson HC, Antshel KM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2):188–200.
European PKU Guidelines 2017: van Wegberg AMJ, MacDonald A, Ahring K, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12:162.
AHRQ Systematic Review: Agency for Healthcare Research and Quality. Adjuvant Treatment for Phenylketonuria. Evidence Report/Technology Assessment.
PKU-003 (sapropterin): Levy HL, Milanowski A, Chakrapani A, et al. Efficacy of sapropterin dihydrochloride (6R-tetrahydrobiopterin) for reduction of phenylalanine concentration in patients with phenylketonuria. Lancet. 2007;370(9586):504–510.
Pegvaliase Phase 1 (Longo 2014): Longo N, Harding CO, Burton BK, et al. Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial. Lancet. 2014;384(9937):37–44.
PRISM-1 / PRISM-2 (pegvaliase Phase 3): Thomas J, Levy H, Amato S, et al. Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM). Mol Genet Metab. 2018;124(1):27–38. (NCT01819727 / NCT01889862)
PKU genotype-phenotype database: Blau N, et al. PAHdb and BIOPKU databases for genotype-phenotype correlations in PKU.

External links notice: Links to government agencies, academic institutions, and private organizations are provided for informational convenience. Linking does not constitute endorsement by Trouvera, and we cannot attest to the accuracy of external content. You will be subject to the destination site’s privacy policy when you leave this site.

What This Guide Does Not Know

An honest guide names its own limits:

This guide cannot replace your metabolic team. It does not know your specific PAH mutations, dietary tolerance, blood Phe history, or comorbidities. Only your metabolic physician and dietitian can build an actual management plan.
PKU research is evolving rapidly. Gene therapy trials, new pharmacological agents, and updated guidelines may change recommendations. Verify all information with your medical team and primary sources.
Drug availability varies by country. This guide focuses primarily on FDA-approved therapies. Access differs in Europe, Asia, Canada, and other regions.
Individual responses vary. Two patients with the same PAH mutations can have different Phe tolerances, BH4 responsiveness, and treatment responses.
Insurance coverage is inconsistent. Medical formula, low-protein foods, and pharmacological therapies may or may not be covered depending on your state and insurance plan. Advocacy organizations can help navigate coverage.

A final word. PKU is one of medicine’s great success stories — a condition that once caused severe intellectual disability is now manageable with dietary treatment, and increasingly treatable with pharmacological therapies. With three FDA-approved medications (sapropterin, pegvaliase, and now sepiapterin), gene therapy in clinical trials, and a supportive medical community, the future for people with PKU has never been brighter. Stay on diet. Take your formula. Monitor your Phe. Connect with the PKU community. And keep asking your metabolic team about new options.

A Research Guide forLiving with Phenylketonuria